Skip to main content
TrialFinder
TrialFinder is for informational purposes only and does not provide medical advice. Always talk to your doctor about whether a trial is right for you.
RECRUITINGOBSERVATIONAL

Study That Will Evaluate the Brazilian Population With COPD.

Prospective Multicentric Cohort Study of Severe and Very Severe COPD Patients in Brazil.

Important: This information is not medical advice. Talk to your doctor about whether a clinical trial is right for you.

About This Trial

Observational, prospective, multicenter cohort study with consecutive inclusion of COPD patients. Eligible patients will be those with severe and very severe COPD according to the GOLD 2024 (Global Initiative for Chronic Obstructive Lung Disease) guidelines being followed at participating hospitals. The severity of COPD is related to the exacerbation rate, which in turn is related to the progression of the disease and the occurrence of complications and death. There is no national data on this subgroup.

Who May Be Eligible (Plain English)

Who May Qualify: - Patients of both sexes, aged 18 years or older, with confirmed COPD according to GOLD 2024: previous or current exposure and spirometry (FEV1/FVC =2 or CAT \>=10); or - GOLD E (\>=2 moderate or 1 severe exacerbation - hospitalization); or - GOLD 3 and 4 (FEV1 \<50%). Who Should NOT Join This Trial: - Advanced fibrosing interstitial lung disease (extent \>=50%); and/or - High-risk pulmonary hypertension (on triple therapy); and/or - Active cancer - on systemic therapy Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language
Inclusion Criteria: * Patients of both sexes, aged 18 years or older, with confirmed COPD according to GOLD 2024: previous or current exposure and spirometry (FEV1/FVC =2 or CAT \>=10); or * GOLD E (\>=2 moderate or 1 severe exacerbation - hospitalization); or * GOLD 3 and 4 (FEV1 \<50%). Exclusion Criteria: * Advanced fibrosing interstitial lung disease (extent \>=50%); and/or * High-risk pulmonary hypertension (on triple therapy); and/or * Active cancer - on systemic therapy

Locations (10)

Research Site
Aparecida de Goiânia, Brazil
Research Site
Bahia, Brazil
Research Site
Belém, Brazil
Research Site
Brasília, Brazil
Research Site
Campo Grande, Brazil
Research Site
Florianópolis, Brazil
Research Site
Goiânia, Brazil
Research Site
Santo André, Brazil
Research Site
São Paulo, Brazil
Research Site
Uberlândia, Brazil